An interventional study of glucose and moxifloxacin in Diabetes Type 2, Hyperglycaemia (Diabetic) and QT Interval, Variation in, sponsored by Richmond Pharmacology Limited. Terminated at 1 site in United Kingdom. Open to participants aged 18 Years to 64 Years. Per ClinicalTrials.gov, last updated 2026-07-01.
Sponsored by Richmond Pharmacology Limited · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom — 57 open to participants now, 73 under way, 20 of them phase 3. Diabetes Mellitus, Type 2 · United Kingdom.
Among the 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, this one is the 463rd largest by enrollment of the 495 interventional ones that give a count, is one of 20 that started in 2023, is one of 155 with no phase, and was the 510th registered.
10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →57 of the 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom are open now. Recruiting first, the newest first:
Imperial College London · Sites in United Kingdom
Ages 18+
Ascletis Pharma (China) Co., Limited · Sites in United Kingdom, United States, Czechia and 3 more countries
Ages 18+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 8 more countries
Ages 18+
Novo Nordisk A/S · Sites in United Kingdom, United States, Argentina and 13 more countries
Ages 45+
AstraZeneca · Sites in United Kingdom, United States, Argentina and 13 more countries
Ages 18+
A study can be open while its sites in United Kingdom have not opened yet or have stopped. Only those recruiting at a site in United Kingdom →
Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.
This study: 18 Years to 64 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
572 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 39 · Phase 2 59 · Phase 3 187 · Phase 4 58
First in 1997; this study’s year is marked. 20 started in 2023.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 14 is below the median of 80 across 8,361 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 207 across the 495 interventional studies, 593 across the 77 observational. Of the 462 that completed or were terminated, 194 (42%) have results posted.
This tab as a report to print or save as PDF → With an account.
345 of 572 have an industry lead sponsor. The 10 most frequent:
Richmond Pharmacology Limited is the lead sponsor of 2 studies on the registry; none are open to participants now.
Richmond Pharmacology Limited has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
16 of the studies in Diabetes Mellitus, Type 2 with a site in United Kingdom that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07400653Phase 3PfizerA Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D) | 2027-10-12 |
| NCT03811561Phase 3Novo Nordisk A/SA Research Study to Look at How Semaglutide Compared to Placebo Affects Diabetic Eye Disease in People With Type 2 Diabetes | 2027-11-07 |
| NCT06652763University of LeicesterManganese-enhanced Magnetic Resonance Imaging (MEMRI) in Heart Failure With Preserved Ejection Fraction | 2026-11 |
Add all 16 to your calendar (.ics) → With an account.
Among the 572 studies in Diabetes Mellitus, Type 2 with a site in United Kingdom, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Diabetes is a significant risk factor for sudden cardiac death, with the QTc interval on electrocardiograms (ECGs) often prolonged in diabetic patients due to factors such as hyperglycaemia and insulin resistance. Drugs like moxifloxacin can further exacerbate this effect, especially in those with diabetes. A previous trial on Type 1 diabetes suggested that hyperglycaemia and moxifloxacin have additive effects, prompting an investigation into whether similar effects occur in Type 2 diabetes (T2DM), particularly in individuals with high insulin resistance. This study aims to evaluate whether moxifloxacin-induced QT-prolongation is amplified by elevated blood glucose levels or insulin deficiency in T2DM patients, considering potential differences between sexes. Blood biomarkers will be analysed to understand the underlying molecular mechanisms. The trial will involve at least 24 male and female participants with insulin-resistant T2DM, aged 18 to 64 years, conducted at Richmond Pharmacology Ltd. Participants will receive treatments with glucose, moxifloxacin, and placebos while closely monitored for side effects during an inpatient stay, followed by outpatient appointments.
Diabetes has been established as a key independent risk factor for sudden cardiac death, a common cause of death from cardiovascular disease. The underlying mechanisms for this seem to be complex and multifactorial, but a change in the electrocardiogram (ECG)(which measures the electrical activity of the heart) parameter called QTc interval has been identified as potentially having a significant role. In patients with diabetes, QT interval prolongation is frequently reported. High blood glucose levels (hyperglycaemia) and insulin resistance (the condition where the body does not respond well to insulin) are thought to be important causes. The investigators also know that some drugs e.g., moxifloxacin (a common antibiotic) can prolong the QT interval and this effect can be more pronounced in patients with diabetes.
The investigators have previously conducted a trial on Type 1 diabetes showing that the effects of hyperglycaemia and moxifloxacin were additive. This led to our hypothesis that similar effects might be observed in type 2 diabetes (T2DM), specifically in those with high insulin resistance. Understanding whether the well-established QT-prolongation caused by moxifloxacin is exaggerated by elevated levels of blood glucose alone or by an insulin deficiency is important for evaluating the risk to patients with T2DM and the potential prevention of cardiac complications. The investigators would also like to determine if the effect varies between sexes and gain a comprehensive understanding of the molecular factors driving these differences by analysing blood biomarkers.
This trial will be conducted at Richmond Pharmacology Ltd. involving a minimum of 24 male and female participants with insulin-resistant T2DM, aged 18 to 64 years. The participants will stay in the clinical trials unit, receive treatments with glucose, moxifloxacin, and placebos and will be monitored closely for any side effects. Following the inpatient stay, participants will return to the unit for an outpatient appointment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Male or female patients with stable T2DM. Diagnosis of T2DM confirmed by:
i. Established diagnosis of T2DM documented on medical records and at screening ≥ 48 mmol/mol (6.5%) and ≤ 80 mmol/mol (9.5%). Subjects with HbA1c levels > 80 mmol/mol but ≤ 90 mmol/mol will be considered eligible, subject to approval by an endocrinologist. AND ii. Evidence of high insulin resistance as defined by a HOMA2-IR score within the top quintile of the locally defined cohort, >0.55 (see Appendix 2).
Stable patients with insulin resistant type 2 diabetes treated with one of the following:
a. Diet and exercise alone, b. Anti-glycaemic monotherapy on metformin, DPP-4i, pioglitazone, an SU or an SGLT-2i.
Participants must agree to use the following requirements for the applicable duration:
Female participants of childbearing potential (WOCBP) who anticipate being sexually active with a male during the trial (from one complete menstrual cycle prior to the first drug administration until three months after the last drug administration) *: CONTRACEPTION REQUIRED: Highly effective contraception must start one complete menstrual cycle prior to the first day of dosing and continue until three months after drug administration. Highly effective contraception methods for WOCBP include:
Combined i.e. (oestrogen- and progestogen-containing) hormonal contraception associated with inhibition of ovulation: **
Progestogen-only hormonal contraception associated with inhibition of ovulation**
Male participants, who anticipate being sexually active during the trial period (from first drug administration until three months after the last NIMP administration) with a woman who is either a WOCBP, a woman who is pregnant and/or breast feeding: CONTRACEPTION REQUIRED: From the first day of dosing until the end of the systemic exposure of the trial drug (for this trial this is until the follow-up visit). Acceptable methods are:
Exclusion Criteria:
Any clinically important abnormalities in rhythm, conduction or morphology of resting ECG that may interfere with the interpretation of QTc interval changes. This includes participants with any of the following (at screening,
Day-1, or pre-dose on Day 1):
Has vital signs outside of the following normal range at screening, Day -1, or
Day 1 pre-dose:
- Blood pressure (BP):
Supine BP (after at least 5 minutes of supine rest):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
HbA1c
A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive glucose (controlled hyperglycaemia) and moxifloxacin placebo on Day 1. On Days 1 and 3 glucose will be administered intravenously and/or orally with the aim of gradually raising glucose concentration to 25-28 mmol/L over the space of an hour. The 25-28 mmol/L glucose level will be maintained for 1 hour. Intravenous glucose rate will be titrated up and down during the first hour as guided by glucose readings on CGMS/VBG. Glucose will be continuously monitored to guarantee concentration levels are maintained stable. At the 2-hour timepoint (H2), intravenous glucose will be terminated, and blood glucose level will be allowed to start reducing.
Drug: glucose
intravenous glucose in combination with intravenous moxifloxacin (300 mg infused over 45 minutes) on Day 3
Drug: glucose · Drug: moxifloxacin
Participants will receive treatments with glucose or matching placebo (please see study design section).
Participants will receive moxifloxacin or matching placebo (please see study design section).
Clinically significant ECG morphology and interval changes from baseline
ECG Analysis Mean QT/QTc values will be calculated for each time point (triplicate ECG) for subsequent analyses. Telemetry data gathered during the study may be used in the optional exploratory analysis of drug related QT/QTc interval changes. The primary baseline corrections will be calculated using averaged QTc pre-dose baseline values (three pre-dose time points). This single value will be used to calculate ΔQTc. A supplementary analysis to calculate ΔΔQTc may be performed using pooled placebo data. The effect on QTc will be calculated using concentration-effect analysis based on the placebo-corrected change from average baseline.
Time frame: Specified timepoints for 4 days and at follow up visit on Day10-D17
Cardiac intervals/subintervals calculated using concentration-effect analysis on Days 1, 2, and 3.
The primary baseline corrections will be calculated using averaged QTc pre-dose baseline values (three pre-dose time points). This single value will be used to calculate ΔQTc. A supplementary analysis to calculate ΔΔQTc may be performed using pooled placebo data. The effect on QTc will be calculated using concentration-effect analysis based on the placebo-corrected change from average baseline.
Time frame: Specified timepoints for 3 days
The paired PK of blood glucose and moxifloxacin (Cmax)
PK parameter: Maximum observed plasma concentration (Cmax) * Glucose * Day 1: Cmax * Day 2: Cmax * Day 3: Cmax * Day 4: Cmax * Moxifloxacin * Day 3: Cmax * Day 4: Cmax
Time frame: 4 Days
The paired PK of blood glucose and moxifloxacin (Tmax)
PK parameter: time to reach maximum plasma concentration (Tmax) * Glucose * Day 1: Tmax * Day 2: Tmax * Day 3: Tmax * Day 4: Tmax * Moxifloxacin * Day 3: Tmax * Day 4: Tmax
Time frame: 4 days
The paired PK of blood glucose and moxifloxacin (AUC)
PK parameter: Area under the plasma concentration-time curve (AUC). * Glucose * Day 1: AUC * Day 2: AUC * Day 3: AUC * Day 4: AUC * Moxifloxacin * Day 3: AUC * Day 4: AUC
Time frame: 4 days
Cardiac interval/subinterval parameters
Cardiac interval/subinterval parameters (QTcF, JTpc, TpTe) prior to glucose administration compared to post-administration
Time frame: 4 days
Comparison of the PK of blood glucose and moxifloxacin with cardiac interval/subinterval parameters and ECG morphology between sexes on Days 1, 2, 3 and 4
Comparison between males and females of the paired PK blood glucose and moxifloxacin, and cardiac interval/subinterval parameters (QTcF, JTpc, TpTe) prior to glucose administration compared to post-administration. PK parameters include maximum observed plasma concentration (Cmax), time to reach maximum plasma concentration (tmax), area under the plasma concentration-time curve (AUC). * Glucose * Day 1: Cmax, tmax, AUC * Day 2: Cmax, tmax, AUC * Day 3: Cmax, tmax, AUC * Day 4: Cmax, tmax, AUC * Moxifloxacin * Day 3: Cmax, tmax, AUC * Day 4: Cmax, tmax, AUC * QTcF, JTpc, TpTe o Days 1, 2, and 3.
Time frame: Specified time points over 4 days
• Concentration effect analysis between male and female volunteers on Days 1, 2, 3 and 4
Comparison of males vs females of the primary baseline corrections calculated using averaged QTc pre-dose baseline values (three pre-dose time points). This single value will be used to calculate ΔQTc. A supplementary analysis to calculate ΔΔQTc may be performed using pooled placebo data. The effect on QTc will be calculated using concentration-effect analysis based on the placebo-corrected change from average baseline.
Time frame: specified timepoints over 4 days
The incidence of treatment-emergent adverse events (TEAEs)
Proportion of participants with clinically significant changes in laboratory safety tests (haematology, chemistry, coagulation and urinalysis), proportion of participants with morphological and/or rhythm abnormalities on ECG, proportion of participants with clinically significant changes in ECG time intervals (PR, QRS, QT and QTc intervals) and proportion of participants with clinically significant changes in vital signs (systolic blood pressure, diastolic blood pressure, pulse rate, respiratory rate and tympanic temperature).
Time frame: From screening to follow up approximately 75 days
To gain a comprehensive understanding of the molecular factors driving differences between male and female participants, by analysing a set of relevant biomarkers: insulin, C-peptide and glucagon.
Change from baseline for individual biomarkers over time, correlated with changes in blood glucose and QTc interval parameters, ECG morphology and concentration effect analysis.
Time frame: 3 days
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from Apr 2023 to primary completion in May 2026, 37 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Moxifloxacin
Richmond Pharmacology Limited